This episode examines innovative therapeutic approaches for treating severe thermal burns, focusing on reducing the need for traditional autografting. One study highlights the safety and efficacy of StrataGraft, a bioengineered skin substitute that successfully promoted wound closure in a majority of adult patients with deep partial-thickness burns. Another research paper compares the outcomes of using autologous skin cell suspensions (ASCS) with different dressing types, specifically evaluating contact layer dressings against poly-lactic acid dressings (PLAD). The findings indicate that utilizing PLAD alongside cell suspensions significantly lowers infection rates, shortens hospital stays, and reduces overall medical costs. Together, these articles suggest that advancing skin substitute technology and optimizing post-surgical dressings can improve clinical recovery while sparing healthy donor skin. This collective research underscores a shift toward biosynthetic solutions that simplify burn management and enhance patient outcomes in real-world medical settings. DISCLAIMER The Critical Edge is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease, nor does it substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider—always seek in-person evaluation and care from your physician or trauma team for any health concerns. DONOR-SPARING COVERAGE FOR DEEP PARTIAL-THICKNESS AND LARGE BURNS STUDY GUIDE TOP TEN TAKEAWAYS 1. StrataGraft is a bioengineered bilayer construct used as a single application on deep partial-thickness (DPT) burns that still have intact dermal elements, with the explicit goal of avoiding or minimizing autograft harvest. 2. In the StrataCAT expanded-access cohort (n = 52; 3–50% TBSA), 88.5% of patients achieved complete wound closure without additional autografting; only 11% needed partial autograft at incomplete sites. 3. Confirmed closure by week 12 occurred in 63.5% of patients (71.9% of treatment sites); durable closure by week 24 occurred in 55.8% of patients (60.4% of sites). 4. Safety was consistent with ordinary burn-unit morbidity: 88.5% had at least one TEAE (most often mild pruritus); 19.2% had serious TEAEs, none attributed to StrataGraft; four deaths were unrelated. 5. Prior RCTs (STRATA2011, STRATA2016) already showed that most DPT wounds treated with StrataGraft needed no autograft by day 28 and closed at rates comparable to autograft by month 3; StrataCAT extends that experience into a real-world, broader-access population. 6. Autologous skin cell suspension (ASCS) expands a small thin donor harvest at approximately 1:80 and can be used alone or with split-thickness skin graft (STSG) on larger TBSA injuries. 7. The kit’s default contact-layer dressing (CLD) is prone to poor adherence, fluid pooling, and infection; a poly-lactic acid biosynthetic dressing (PLAD) adheres more closely, permits fluid egress, and functions as a temporary epithelial barrier. 8. In a single-center before-after cohort of ≥10% TBSA burns treated with ASCS (± STSG), PLAD versus CLD was associated with shorter length of stay (17 vs 29 days) and fewer postoperative wound infections (approximately 7–9% vs 32–39%). 9. After adjustment for grafted area and TBSA, CLD carried an 8-fold higher odds of postoperative infection; antibiotic days were also substantially shorter with PLAD (0.47 vs 4.39 days). 10. Inflation-adjusted charges per %TBSA trended lower with PLAD ($18,459 vs $25,396); the biologic dressing therefore functions as both a clinical and a resource intervention, not merely a coverage layer. STUDY GUIDE I. StrataGraft for Deep Partial-Thickness Burns with Intact Dermis Autograft remains the reference standard for definitive closure of deep burns, but donor-site morbidity—pain, infection, hypertrophic scar, and limited harvestable skin in the elderly or the thin-skinned—creates a standing need for donor-sparing alternatives. StrataGraft is a bioengineered, bilayered skin substitute applied as a single, meshed (≤1:1) sheet to DPT wounds that retain dermal elements. Earlier controlled studies (STRATA2011 Phase 1b, n = 30; STRATA2016 Phase 3, n = 71) established that most treated sites required no autograft by day 28 and that three-month closure rates approximated those of autograft, with a TEAE profile typical of burned patients. A. StrataCAT design StrataCAT (NCT04123548) was a Phase 3b, open-label, single-arm, multicenter expanded-access study intended to maintain product availability after the pivotal trials and to enlarge real-world safety experience. Fifty-two adults with 3% to less than 50% TBSA thermal burns received one application of StrataGraft and were followed for 24 weeks. The primary endpoint was the count and percentage of patients with treatment-emergent adverse events. Efficacy endpoints (confirmed and durable wound closure, need for rescue autograft, scar scores) were descriptive; the study was neither designed nor powered as a comparative efficacy trial. B. Safety At least one TEAE occurred in 88.5% of patients; mild pruritus was the most frequent. Twenty serious TEAEs occurred in 10 patients (19.2%); none were judged related to StrataGraft. Four deaths (7.7%)—aspiration, myocardial infarction, self-injury, and Gram-negative rod sepsis—were unrelated. The safety signal therefore remains that of the underlying burn injury and its comorbidities, not of the construct itself. C. Closure and donor-site sparing Complete wound closure without additional autograft was achieved in 88.5% of patients. Confirmed closure by week 12: 33 patients (63.5%; 95% CI 50.4–76.5%) and 69 treatment sites (71.9%). Durable closure by week 24: 29 patients (55.8%; 95% CI 42.3–69.3%) and 58 sites (60.4%). Six patients (11%) required partial autograft for incomplete sites. Patient- and observer-reported scar scores were stable through follow-up. D. Limitations that constrain interpretation No concurrent comparator arm; sample insufficiently diverse by race and Fitzpatrick type to support scar-outcome claims by skin type; COVID-era restrictions limited in-person observer scoring. The authors correctly frame the result as a favorable benefit-to-risk balance and donor-site sparing in adults with DPT burns that retain dermal elements, not as a license for use on full-thickness wounds or massive TBSA injuries until larger comparative data exist. II. Dressing Choice Over Autologous Skin Cell Suspension in Larger Burns ASCS is a point-of-care device that converts a small, thin donor harvest into a sprayable cell suspension with roughly 1:80 expansion. It is used either as sole coverage or in combination with widely meshed STSG. The manufacturer-supplied contact-layer dressing is the historical default cover. PLAD is a biosynthetic sheet designed to mimic epithelium: it adheres tightly, is microporous enough to prevent exudate pooling, and presents a barrier to exogenous contamination. Larson and colleagues asked whether swapping CLD for PLAD changed infection, length of stay, and cost in burns ≥10% TBSA. A. Cohort and practice change Single-center retrospective cohort, January 2019–October 2022. All patients with ≥10% TBSA burns who underwent excision and ASCS were included. From 2019 through 2021 the cover was CLD; thereafter it was PLAD. Use of concomitant STSG was at surgeon discretion and did not differ significantly between eras (89% CLD vs 79% PLAD). Seventy-one patients were analyzed (28 CLD, 43 PLAD); mean TBSA 22.5%; mean grafted area approximately 3,641 cm² and comparable between groups. B. Length of stay Overall mean LOS was 22 days. CLD patients stayed 29 days versus 17 days with PLAD (p = 0.0079). Univariate predictors of LOS included dressing type, use of STSG, total area grafted, age, comorbidity, and %TBSA. In multivariate analysis, PLAD remained independently associated with shorter stay. C. Infection and antibiotic exposure Postoperative wound infection was substantially more common under CLD (user-reported 39% vs 9%, p = 0.006; corresponding abstract figures 32% vs 7%, p = 0.009). After adjustment for grafted area and TBSA, the odds of infection were 8.1 times higher with CLD (p = 0.015). Mean antibiotic days were 4.39 versus 0.47 (p = 0.0074). Univariate predictors of infection were dressing group, grafted area, and %TBSA; multivariate analysis again isolated PLAD as protective. D. Resource use Absolute mean charges were higher in the CLD era ($737,839 vs $494,447) but not statistically significant. Inflation-adjusted charges per %TBSA trended lower with PLAD ($18,459 vs $25,396, p = 0.062). The authors attribute the clinical differences to PLAD’s closer wound-bed contact, barrier function, and fluid-egress properties—features the contact layer lacks. E. Practical caveats This is a before-after, single-center, non-randomized comparison. Era effects (improved excision technique, infection-control practice, or case-mix drift) cannot be fully excluded. Concomitant STSG use was common in both groups, so the result should be read as “PLAD over ASCS ± STSG,” not as a pure ASCS-versus-graft trial. Even so, the magnitude of the infection and LOS differences is large enough that many burn units have already changed default coverage over cell-suspension applications. III. How the Two Technologies Fit Together StrataGraft and ASCS-plus-PLAD address overlapping but not identical problems. StrataGraft is a manufactured bilayer intended for DPT wounds that still have a dermal scaffold; its value is elimination of a donor site on that wound. ASCS is a point-of-care expansion tool for larger or mixed-depth injuries where some autograft is still required or where widely meshed STSG needs an epidermal “spray.” PLAD is not a substitute for either construct; it is the co
